Trial Profile
A phase I study of CD40LGVAX in patients with non-small cell lung cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2015
Price :
$35
*
At a glance
- Drugs CD40L GVAX (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 15 Jun 2015 New trial record